

Supplementary table: Outcomes of ICI rechallenge

Initial irAEs (n)	Same irAE after rechallenge	New irAE after rechallenge	Same and new irAE after rechallenge	no irAE recurrence
Gastro-intestinal disorders (47)	20	6	1	20
Colitis (37)	17	4	1	15
Pancreatic disorders (9)	3	2		4
Gastritis (1)				1
Endocrine disorders (34)	2	4		28
Hyperthyroidism (12)	1	1		10
Hypophysitis (9)	1	1		7
Hypothyroidism (5)		2		3
Diabetes (4)				4
Adrenal insufficiency (4)				4
Hepatitis (31)	6	7		18
Respiratory disorders (21)	5	2		14
Pneumonitis (18)	5	1		12
Pulmonary sarcoidosis (2)		1		1
Pulmonary embolism (1)				1
Skin disorders (18)	9	2		7
Lichenoid dermatitis (5)	3	1		1
Rash/inflammatory dermatitis (4)	1			3
Psoriasis (3)	1			2
Bullous pemphigoïd (2)	1			1
Vasculitis (1)	1			
Cellulitis (1)	1			
Erythema multiforme (1)	1			
Lupus (1)		1		
Musculoskeletal disorders (11)	4			7
Arthralgia/arthritis (9)	3			6
Myositis (2)	1			1

Renal and urinary disorders (10)	3		1	6
Nephritis (9)	2		1	6
Cystitis (1)	1			
Hematological disorders (6)		1	1	4
Hemophagocytic syndrome (2)				2
Hemolytic anemia (1)				1
Thrombocytopenia (1)			1	
Neutropenia (1)				1
Thrombocytopenic purpura (1)		1		
Neurological disorders (6)	1			5
Myasthenia (2)				2
Vestibular syndrome/neuritis (2)				2
Aseptic meningitis (1)				1
Encephalopathy (1)	1			
Ocular disorders (5)	1			4
Uveitis (2)				2
Dry eye syndrome (2)	1			1
Optic neuritis (1)				1
Cardiac disorders (2)	1			1
Myocarditis (1)	1			
Ventricular dysfunction (1)				1
Total (191)*	52	22	3	114

*191 irAEs led to ICI discontinuation in 180 patients.